IL-2 is crucial to T cell homeostasis, especially of CD4 + T regulatory cells and memory CD8 + cells, as evidenced by vigorous proliferation of these cells in vivo following injections of superagonist IL-2/anti-IL-2 antibody complexes. The mechanism of IL-2/anti-IL-2 antibody complexes is unknown owing to a lack of understanding of IL-2 homeostasis. We show that IL-2 receptor α (CD25) plays a crucial role in IL-2 homeostasis. Thus, prolongation of IL-2 half-life and blocking of CD25 using antibodies or CD25-deficient mice led in combination, but not alone, to vigorous IL-2-mediated T cell proliferation, similar to IL-2/anti-IL-2 antibody complexes. These data suggest an unpredicted role for CD25 in IL-2 homeostasis.
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CD25 | cytokine | cytokine/mAb complexes | T cell homeostasis | Fc receptor I L-2 is central to the proper functioning of the immune system by participating in T cell homeostasis and optimizing immune responses (1, 2) . IL-2 receptors (IL-2R) consist typically of three receptor subunits termed IL-2Rα (CD25), IL-2Rβ (CD122), and the common gamma chain (γ c , CD132) (3) (4) (5) . Notably, CD122 and γ c are crucial for signal transduction, whereas CD25 is not essential for IL-2 signaling but instead confers high-affinity binding of IL-2 to its receptor, thereby increasing receptor affinities by about 10-to 100-fold (5-7). High-affinity αβγ IL-2Rs are typically found on CD4 + T regulatory cells (Tregs) as well as recently-activated T cells (1, 2) . Low-affinity βγ IL-2Rs are present at a low level on naïve CD8 cells but are prominent on antigen-experienced (memory) and memory-phenotype (MP) CD8 + T cells as well as natural killer (NK) cells (1, 2) . Both MP CD8 + T cells and NK cells express very high levels of CD122 and readily respond to IL-2 injections in vivo (8) . The vast majority of IL-2 is generated by activated T cells, especially CD4 + cells, with a minor contribution from NK and NK T cells (1, 3, 9) . Thus, IL-2 is typically produced by recently-activated T cells and acts in an autocrine or paracrine fashion on these cells, many of which up-regulate CD25 expression upon T cell receptor stimulation (3) .
Because of its potent stimulatory properties, IL-2 is subjected to a tight regulation. With regard to IL-2 half-life, renal metabolism has been reported to play an important role in eliminating IL-2 after i.v. injection (10) . Thus, for exogenously-administered IL-2, renal elimination results in a very short in vivo half-life of IL-2 in the range of minutes. This has been a major limitation for IL-2-based strategies in the treatment of metastatic cancer and chronic viral infections, thus requiring the use of high doses of IL-2, which, however, can cause severe toxic side effects, termed vascular leak syndrome (11, 12) . In an attempt to extend in vivo halflife and increase biological activity, IL-2 has been coupled to larger proteins such as albumin and unrelated antibodies to create IL-2-IgG fusion proteins (IL-2-FP) (12, 13) , although with limited success.
Recently, injection of IL-2 bound to particular anti-IL-2 monoclonal antibodies (mAbs) was found to greatly enhance the biological activity of IL-2 in vivo, leading either to vigorous proliferation of MP CD8 + T cells and NK cells or expansion of CD25 + CD4 + Tregs (8) . Notably, anti-IL-2 mAbs typified by S4B6 and MAB602, specific to mouse (m) and human (h) IL-2, respectively, formed IL-2/mAb complexes that preferentially bound to MP CD8 + T cells and NK cells expressing high levels of CD122 along with γ c (8) . We will refer to these CD122-directed complexes as IL-2/mAb CD122 complexes. In contrast, JES6-1 anti-mIL-2 mAb produced IL-2/mAb complexes that interacted almost exclusively with immune cells expressing high levels of CD25 along with βγ IL-2R; these CD25-directed complexes, designated IL-2/mAb CD25 complexes, induced selective expansion of CD25 + CD4 + Tregs (8) . In addition to IL-2, cytokine/mAb complexes can also be generated using IL-3, IL-4, IL-6, or IL-7, which have been successfully used in various animal models, including viral infections, antitumor responses, autoimmune disease, and graft tolerance (8, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) .
Despite the considerable interest in IL-2/mAb complexes arising from its broad applications, the exact nature of the underlying mechanism of IL-2/mAb complexes remains elusive. Several mechanisms have been proposed, including protection from enzymatic alteration of the active site, cytokine presentation by Fc receptor (FcR)-bearing cells, and prolongation of in vivo IL-2 half-life, with some evidence supporting the latter (12, 15, 16) .
Here, we show that the in vivo activity of IL-2/mAb CD25 complexes crucially depended on the presence of neonatal FcR (FcRn), whereas for IL-2/mAb CD122 complexes, it was a result of prolonged IL-2 half-life and protection from interaction with CD25. These results also suggest an unanticipated role for CD25 in the regulation of IL-2 homeostasis.
Results
Role of FcR on in Vivo Activity of IL-2/mAb Complexes. As mentioned above, two types of IL-2/mAb complexes with distinct biological activities have been described, namely IL-2/mAb CD122 complexes, generated using S4B6 anti-mIL-2 or MAB602 anti-hIL-2 mAbs, and IL-2/mAb CD25 complexes generated using JES6-1 anti-mIL-2 mAb (8). IL-2/mAb complexes using either mIL-2 or hIL-2 yielded similar results when compared and hence will be described here without specifying the species of IL-2 (this information can be found in the legends for Figs. 1-6 ). (Fig. 1A) . Also, strong expansion of donor cells was observed in FcRI (Fig. 1A) . (Fig. 1B) . Residual FcRn expression on donor T cells was unlikely to play a role, as similar findings were observed with FcRn −/− donor T cells. These findings indicate that for IL-2/mAb CD122 complexes, FcRn play a partial role in mediating their in vivo activity. This conclusion is consistent with a previous report using β2-microglobulin-deficient mice (24) . Moreover, animals deficient in both types of FcR, namely FcRI (30), this finding strongly suggests that mAb-induced extension of IL-2 lifespan is a major mechanism for the strong biological activity of IL-2/mAb complexes.
IL-2/mAb Complexes Display an Extended in Vivo
Lifespan. In the absence of FcRn, serum half-life of IgG decreases to 1-1.5 days, compared to approximately 6-8 days under normal conditions (27) . Therefore, the above findings on the role of FcRn could indicate that mAb-induced prolongation of in vivo IL-2 lifespan is an important mechanism for the potent activity of IL-2/mAb complexes (14) (15) (16) 24) , especially in the case of IL-2/mAb CD25 complexes.
To investigate this idea, the in vivo lifespan of IL-2/mAb complexes was compared to IL-2 in WT hosts by two complementary approaches. First, a bolus of a high dose of IL-2 (20 μg) or a standard dose of IL-2/mAb CD122 complexes (1.5 μg/15 μg) was administered to WT mice at various intervals before injection of carboxyfluorescein succinimidyl ester (CFSE)-labeled MP CD8 + T cells. Measuring the proliferation of donor T cells 3 days later revealed that the activity of IL-2 alone tapered off rapidly after 4 h, whereas the activity of IL-2/mAb CD122 complexes was still evident even after 24 h ( Fig. 2A) .
The second approach involved the use of IL-2-sensitive CTLL-2 cells for measuring IL-2 activity in the serum of mice at different time-points after injection of IL-2. This approach is reasonable as CTLL-2 cells did not respond to endogenous amounts of cytokines present in the normal mouse serum and, more importantly, displayed a comparable sensitivity to IL-2 and both forms of IL-2/mAb complexes (Fig. S2) . Here, two different doses of IL-2 (15 μg vs. 1.5 μg) and of IL-2/mAb CD122 complexes (1.5 μg/15 μg vs. 0.3 μg/3 μg) were administered to assess the effect of cytokine concentration on in vivo lifespan. In line with above results using CFSE-labeled MP CD8 + T cells, serum halflife of IL-2 injected at a high dose (15 μg) was found to be approximately 6 h, whereas half-life of the standard dose (1.5 μg) of IL-2/mAb CD122 complexes was approximately 24 h, both for human and mouse IL-2 ( Fig. 2B and Fig. S3 ). The half-life of IL-2 injected at the low dose (1.5 μg) appeared to be shorter (approximately 2 h); because this is the dose used to generate the standard dose of IL-2/mAb CD122 complexes, this result indicated that a 12-fold extension in IL-2 lifespan was achieved through the formation of IL-2/mAb complexes. The half-life measurement of IL-2/mAb CD122 complexes using CTLL-2 cells was therefore comparable to the direct in vivo measurement using MP CD8 + T cells ( Fig. 2A) . Notably, in vivo half-life of the standard dose of IL-2/mAb CD25 complexes, as determined by the CTLL-2 approach, proved to be even longer than for IL-2/mAb CD122 complexes. Thus, IL-2 activity was detectable for up to 72 h for IL-2/mAb CD25 complexes with an estimated half-life of over 48 h (Fig. 2C and Figs. S3 and  S4) . Interestingly, half-life of IL-2/mAb CD122 complexes could be extended to resemble IL-2/mAb CD25 complexes by depletion of CD8 + T cells and NK cells in WT mice (Fig. S4 ), suggesting that consumption by these cell subsets is a limiting factor for the halflife of IL-2/mAb CD122 complexes. Complexes. To further assess the role of extended in vivo IL-2 lifespan in mediating the potent activity of IL-2/mAb CD122 complexes, we tested whether repeated injections of IL-2 would mimic the strong activity of IL-2/mAb CD122 complexes. However, although repeated injections of IL-2 at 2 h intervals for the duration of 24 h displayed significantly more activity than one injection of IL-2, it was still considerably less effective in inducing proliferation of MP CD8 + T cells than one single injection of IL-2/ mAb CD122 complexes (Fig. 3A) . Alternatively, we determined whether repeated injections of IL-2/mAb CD122 complexes generated with F(ab') 2 fragments, which we have previously shown to display minimal activity (8) , would restore the strong activity of intact IL-2/mAb CD122 complexes. Notably, repeated injections of IL-2/mAb CD122 complexes generated with F(ab') 2 fragments were as effective or even more effective than a single injection of intact IL-2/mAb CD122 complexes (Fig. 3B) . Collectively, these results suggest the following two conclusions. First, because the half-life of F(ab') 2 fragment is approximately 6-12 h (31, 32), IL-2/ F(ab') 2 complexes are ineffective mainly because of their short lifespan, thus indicating that extension of IL-2 half-life is an essential mechanism for in vivo activity of IL-2/mAb complexes. Second, and more importantly, repeated injections of IL-2/ F(ab') 2 complexes, but not of IL-2, were able to mimic the potent activity of IL-2/mAb CD122 complexes, thus suggesting that the specific binding of anti-IL-2 mAb is crucial for their strong in vivo activity.
IL-2-IgG Fusion Proteins Have a Long Half-Life but Low Biological
Activity. To further investigate the role of extended IL-2 half-life in contributing to IL-2/mAb CD122 activity in vivo, IL-2/mAb CD122 complexes were compared to a recombinant IL-2-IgG fusion protein (IL-2-FP), designated chTNT-3/IL-2 and comprised of hIL-2 covalently linked to a chimeric anti-nuclear IgG (33) . At an equivalent IL-2 dose, IL-2-FP was found to be more potent than IL-2 alone, but considerably less effective than IL-2/ mAb CD122 complexes in inducing expansion of MP CD8 + T cells (Fig. 4A and Fig. S5 ). Interestingly, this was the case despite the fact that IL-2-FP exhibited similar or even longer in vivo lifespan as IL-2/mAb CD122 complexes (Fig. 4B) . Although these findings support the view that multiple factors are involved in mediating the activity of IL-2/mAb CD122 complexes, these results could also be due to structural differences between these reagents. For instance, unlike IL-2/mAb CD122 complexes, IL-2 in the IL-2-FP is covalently attached to IgG and cannot dissociate.
Thus, we tested whether binding of anti-IL-2 mAb to IL-2-FP might boost the activity of IL-2-FP. Interestingly, complexes of IL-2-FP bound to anti-IL-2 mAb MAB602, designated IL-2-FP/ mAb CD122 complexes, were found to induce much stronger expansion of MP CD8 + T cells than IL-2-FP and even surpassed IL-2/mAb CD122 complexes (Fig. 4C and Fig. S5) . Surprisingly, binding of IL-2-FP to mAb CD122 did not alter the lifespan of IL-2-FP (Fig.  4D) , thus indicating that a significant enhancement of IL-2 activity can be achieved without further increasing the half-life of IL-2.
IL-2/mAb CD122 Complexes Are Protected from Interaction with CD25.
Recently, we found that, in addition to immune cells such as Tregs, nonimmune cells express CD25. Therefore, ubiquitous expression of CD25 may lead to a decrease in IL-2 availability to T cells and NK cells (1, 2) . Accordingly, an additional mechanism by which IL-2/ mAb CD122 complexes, that are recognized by βγ IL-2R irrespective of CD25 expression, display strong activity could be that they avoid interaction with these CD25 + cells. To test this idea, we took advantage of the blocking anti-CD25 mAb PC61. Concomitant injection of IL-2 and anti-CD25 mAb only minimally increased the activity of soluble IL-2 (Fig. 5A) . However, coadministration of anti-CD25 mAb greatly increased the activity of IL-2-FP, leading to proliferation that was almost as intense as with IL-2/mAb CD122 complexes at an equivalent IL-2 dose (Fig. 5A ). Moreover, with repeated IL-2 injections every 2 h, use of anti-CD25 mAb also markedly enhanced the effects of IL-2 (Fig. 5B) .
The above results strongly suggest that preventing interaction of IL-2 with CD25 is a second major mechanism to explain how IL-2/ mAb CD122 complexes mediate their strong activity. Nevertheless, it is notable that the activity of IL-2-FP, and also IL-2 given repeatedly in the presence of blocking anti-CD25 mAb, was still slightly lower than that of IL-2/mAb CD122 complexes (Fig. 5) . To determine whether this difference could be due to an inability of the anti-CD25 mAb to completely neutralize IL-2 interaction with CD25, the activity of IL-2-FP and IL-2/mAb CD122 complexes was directly compared in CD25 −/− mice. One complicating feature of CD25
−/− mice is that their high serum levels of IL-2 are able to induce spontaneous proliferation of adoptively-transferred donor MP CD8 + T cells (34, 35) . To circumvent this problem, the activity of IL-2-FP and IL-2/mAb CD122 complexes was measured in these hosts 3 days after injection of donor T cells, just before the time it takes for donor T cells to undergo cell division in response to host IL-2. Significantly, as assessed by expansion of donor MP CD8 + T cells, the activity of IL-2/mAb CD122 complexes, repeated IL-2 injections, and IL-2-FP were all virtually identical in CD25 −/− hosts (Fig. 6 ).
Discussion
Collectively, these findings suggest that IL-2/mAb CD122 complexes function by extending the half-life of IL-2 and by preventing the interaction of IL-2 with CD25, thus leading to a 40-fold higher in vivo biological activity compared to soluble IL-2. A notable difference between the two distinct IL-2/mAb complexes is that IL-2/ mAb CD25 acutely rely on FcRn, whereas FcRn play only a minimal role for IL-2/mAb CD122 . Because the half-life of IL-2/mAb CD122 complexes could be extended to resemble the half-life of IL-2/ mAb CD25 complexes by depleting CD8 + T and NK cells, it could be hypothesized that consumption by rapidly-dividing MP CD8 + T and NK cells limits the half-life of IL-2/mAb CD122 to approximately 24 h. In contrast, IL-2/mAb CD25 complexes bind selectively to the relatively small population of CD25-expressing cells, mostly CD25 + CD4 + T cells, resulting in a lifespan of about 72 h for these complexes. Thus, the differential consumption of IL-2/mAb complexes might explain their half-life and level of FcRn dependence. This notion is further supported by the observation that the half-life of IL-2/mAb CD25 complexes is significantly reduced in FcRn −/− mice, whereas the half-life of IL-2/mAb CD122 complexes in FcRn −/− mice remains largely unaffected. It should be noted that FcRn become important for serum IgG half-life only after 24-36 h (27) .
According to the literature, IL-2 homeostasis is believed to depend on IL-2 production by T cells and IL-2 elimination by renal metabolism. As mentioned above, IL-2 is mainly produced by activated CD4 + T cells, with a minor contribution by activated CD8 + cells, NK cells, NK T cells, and DCs that have been stimulated by microbial stimuli (1, 2, 9) . Accordingly, the vast majority of IL-2 production in vivo will take place in the secondary lymphoid organs, notably the lymph nodes, and will also be consumed there by proliferating T cells. Hence, under normal conditions, it is unlikely that IL-2 leaks out into the blood and is then eliminated by the kidneys. Thus, normal IL-2 homeostasis might not depend largely on renal elimination but more on absorption by CD25 + cells. Evidence for this idea is provided in this study where repeated i.p. injections of IL-2 led to some proliferation of memory CD8 + T cells, which was further enhanced by concomitant CD25 blockade.
Other evidence for CD25 in IL-2 homeostasis comes from studies using CD25 −/− animals. CD25-deficient mice contain highly elevated serum IL-2 levels (34, 35) . This may be due to the presence of strongly-activated T cells, but the majority of T cells in CD25 −/− mice are resting, slowly-proliferating cells. High serum IL-2 levels in CD25
−/− mice might be due to a lack of CD25 + CD4 + Tregs, thus leading to diminished utilization of IL-2. In line with this idea is the observation that CD25 + CD4 + Tregs are able to deprive effector T cells from cytokines (36), including IL-2, and that transfer of purified CD25 + CD4 + Tregs to CD25 −/− mice led to a reduction of serum IL-2 levels (37). Apart from its presence on Tregs, CD25 on other lymphocytes or on nonimmune cells might also play a role in IL-2 homeostasis. In this context, we found significant CD25 expression on mouse nonimmune cells in vivo. Also, fibroblasts have been reported to express CD25 (2, 38, 39) . Interestingly, injection of IL-2-FP plus anti-CD4 mAb with the aim of depleting CD25 + CD4 + Tregs was not as efficient in stimulating memory CD8 + T cells in vivo as IL-2-FP plus anti-CD25 mAb. Finally, cytokines can also interact with components of the extracellular matrix (ECM), most notably heparan sulfate proteoglycans, which have been reported to bind various cytokines, including IL-1α, IL-1β, IL-2, IL-3, IL-6, IL-7, GM-CSF, and TGF-β1, in addition to chemokines and growth factors (40) (41) (42) (43) (44) . Notably, anti-IL-2 mAbs might mediate some of their effects by influencing the binding of IL-2 to the ECM.
Materials and Methods
Mice. C57BL/6 (referred to as WT) and CD25 −/− mice, on a C57BL/6 background, were obtained from Charles River and The Jackson Laboratory, respectively. IL-7 tg mice on a C57BL/6 background, which express the IL-7 transgene under the control of the mouse MHC class II Eα promoter (45) , were a kind gift of Drs. Daniela Finke (Center for Biomedicine, Basel, Switzerland) and Rod Ceredig (National University of Ireland, Galway, Ireland) and were bred onto a Thy1. Administration of Cytokines, Antibodies, and Fusion Proteins in Vivo. Unless otherwise stated, mice received i.p. injections of 1.5 μg IL-2 or a mixture of 1.5 μg IL-2 plus 15 μg anti-IL-2 mAb. Recombinant mouse IL-2 (rmIL-2) was obtained from eBioscience. S4B6 anti-mIL-2 mAb CD122 was generated from culture supernatants of the S4B6.1 hybridoma and purified from either culture supernatant or ascites fluid on protein G column. F(ab') 2 fragments of S4B6 were prepared as previously described (8) . JES6-1A12 anti-mIL-2 mAb CD25 was obtained from eBioscience. Recombinant human IL-2 (rhIL-2) and MAB602 (clone 5355) anti-hIL-2 mAb CD122 were purchased from R&D Systems. 5344 
